Lennox-Gastaut Syndrome Treatment Market to grow at a CAGR of 4.29% during 2024-2028
The Lennox-Gastaut Syndrome Treatment Market is expected to grow at a CAGR of 4.29% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 699.8 million. In the realm of epilepsy treatment, minimally invasive neurostimulation techniques, such as Vagus Nerve Stimulation (VNS) and Deep Brain Stimulation (DBS), have emerged as promising options for Lennox-Gastaut Syndrome (LGS) patients. These approaches involve the implantation of small devices that deliver electrical impulses to modulate neural activity, potentially reducing seizure frequency. Responsive neurostimulation devices, which can detect abnormal electrical activity in the brain and respond with targeted stimulation, represent a minimally invasive and personalized treatment option. Although not yet widely adopted for LGS, advancements in this technology, including refined imaging techniques like stereotactic imaging for precise diagnosis and treatment planning, are positively impacting treatment strategies for this patient population.
Get more information on Lennox-Gastaut Syndrome Treatment Market by requesting a sample report
Technavio analysts predict that the Non-surgical treatment subsegment will lead the Type segment during 2024 and 2028 In the realm of Lennox-Gastaut Syndrome (LGS) treatment, non-surgical interventions hold significant importance. These approaches encompass medications and dietary therapies. First-line medications for LGS include valproate, topiramate, and lamotrigine. Additionally, felbamate, levetiracetam, rufinamide, and clobazam are frequently prescribed antiseizure medications for early non-surgical treatment. The ketogenic diet, a dietary therapy, is another non-surgical option. Its mechanism of action is not fully understood, but it may decrease LGS symptoms by reducing glutamatergic neuron excitability, lowering carbohydrate levels, and inhibiting mTOR receptors. The adoption of these effective treatment modalities is anticipated to fuel the expansion of the non-surgical treatment segment in the LGS market during the forecast period.
Here are the various ways based on which the market is segmented:
There are several factors that are causing the market to flourish advancements in medical research on lgs
Learn which are the obstacles that the market is experiencing in the way of its growth by accessing the free PDF report
Lennox-Gastaut Syndrome (LGS) is a severe childhood epilepsy syndrome characterized by various neurological features, including cognitive impairment, behavioral problems, and cognitive dysfunction. The LGS treatment market is witnessing significant growth due to the development of novel therapy techniques and the implementation of precision medicine. Several clinical trials are underway to evaluate the efficacy of new pipeline drugs, including cannabidiol, fenfluramine, and retigabine. The disease epidemiology of LGS indicates that it affects approximately 3-5 per 100,000 individuals, with a higher prevalence in children. The market for LGS treatment is segmented into marketed drugs and non-surgical treatment segments. Marketed drugs include valproic acid, topiramate, and ethosuximide, among others. The non-surgical treatment segment is expected to dominate the market due to the chronic nature of the disease and the likelihood of approval of new drugs. The Epilepsy Society highlights the importance of addressing the cognitive and behavioral symptoms of LGS in addition to seizure control. Electroencephalography (EEG) is a crucial diagnostic tool for LGS, and seizures, including tonic-clonic seizures, are a significant challenge for caregivers and patients. Intellectual power and mental retardation are common cognitive impairments in LGS, making it a pediatric epilepsy syndrome with significant impact on daily life. The market for LGS treatment is expected to grow as new therapies are developed to address the complex neurological features of this chronic disease. Pharmacies play a crucial role in ensuring access to these treatments for patients and their caregivers.
According to Technavio, the global Lennox-Gastaut Syndrome (LGS) treatment market is a segment of the expansive global pharmaceuticals market, which encompasses entities involved in research and development (R&D) or manufacturing of various pharmaceutical offerings, including generic, non-generic drugs, and veterinary drugs. The size of the global healthcare industry, which includes the pharmaceuticals sector, is determined by Technavio based on the consolidated revenue generated by providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. The growth of the pharmaceuticals market is anticipated to be driven by several key factors, including the increasing global population aging above 60 years, leading to a rising demand for healthcare and pharmaceutical products.
The Lennox-Gastaut Syndrome Treatment Market is experiencing significant growth, fueled by the advancements in medical research on lgs. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
